Can ACLU Expect to Win Its BRCA Gene Patenting Case Before it Even Gets to Trial? | GenomeWeb

By Turna Ray

In a counter move to Myriad Genetics' motion to dismiss its anti-gene patenting case, the American Civil Liberties Union has submitted numerous declarations of material fact to urge a district court judge to decide that Myriad's BRCA patents are invalid and unconstitutional even before the case even gets to trial.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.